Phase 2/3 trial assesses safety and effectiveness of intravenous efgartigimod in juveniles with myasthenia gravis, indicating potential for optimal dosing.
To present interim results of ADAPT JR (NCT04833894), a Phase 2/3 trial assessing pharmacokinetics, pharmacodynamics, safety, and activity of intravenous (IV) efgartigimod in participants with acetylcholine receptor antibody–positive (AChR-Ab+) juvenile generalized myasthenia gravis (gMG) to confirm an age-appropriate dose in this population.
No takes yet. Share an insight, caveat, or question.
Schwaede et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: